Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06042127 · ClinicalTrials.gov registry record · NA

POEM-F for Achalasia International Study

A NA study of Achalasia, sponsored by Chinese University of Hong Kong.

Recruiting
Registry status
NA
Development phase
81
Enrollment target
7
Study locations

NCT06042127: Recruiting NA study of Achalasia, sponsored by Chinese University of Hong Kong.

NCT06042127 is a NA study of Achalasia that is actively recruiting participants, run by Chinese University of Hong Kong. The registered enrollment target is 81 participants, below the 130-participant average among 7 other Achalasia trials with a reported enrollment target (38% lower). The trial reports 7 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06042127, a NA study of Achalasia, is actively recruiting participants, sponsored by Chinese University of Hong Kong.

RECRUITING
Registry status
NA
Development phase
81 participants
Enrollment target
7
Study locations

Study Summary

Per-oral endoscopic myotomy (POEM) has emerged as the endoscopic treatment of choice for achalasia, offering comparable symptom relief with laparoscopic Heller's cardiomyotomy. The main concern with POEM is the higher incidence of post-procedure gastroesophageal reflux disease (GERD), occurring in up to 50-60% of patients. In order to reduce the risk of GERD, endoscopic fundoplication has been developed as a novel procedure mimicking surgical anterior partial fundoplication that can be performed in the same session as POEM (POEM-F). Case series of POEM-F in patients with achalasia reported encouraging outcomes of low GERD rate of \~12% at 1 year. Prospective comparative data between POEM-F and conventional POEM on post-procedure GERD is current lacking. The investigators therefore designed an international multicenter prospective randomized study to investigate the efficacy of POEM-F. The investigators postulate that POEM-F could reduce the incidence of post-procedure GERD when compared with conventional POEM. This is an international multicenter randomized controlled trial conducted between high volume expert centers from Hong Kong SAR, China, India and United States of America. Adult patients with manometry confirmed achalasia would be randomised to undergo POEM-F or POEM. The procedure would be performed by experts with vast experience in POEM. The primary outcome is the incidence of post-procedure GERD at 1 year, defined by the updated Lyon consensus. Secondary outcomes include technical and clinical success rates, adverse events, post-POEM endoscopic and manometry findings as well as patients' symptom scores. Sample size calculation Based on existing pilot comparative data on POEM-F and POEM, it is estimated that 84 patients would be required to demonstrate a difference in post-procedure GERD of 47.6% to 18.2%, with 80% power and false positive rate of 0.05, accounting for 10% loss to follow-up. Purpose and potential The current study proposal could demonstr

Primary Outcome

Defined by updated Lyon 2.0 consensus as fulfilling one or more of the criteria: 1. Endoscopic erosive esophagitis, LA grade B or above 2. Long segment Barrett's esophagus 3. Peptic esophageal stricture 4. 24-hour pH study with acid exposure time \>6% Both endoscopy and pH study to be performed with proton pump inhibitor stopped for 4 weeks

Conditions Studied

Interventions

  • PROCEDURE POEM-F
  • PROCEDURE Conventional POEM

Study Locations (7)

Other

  • Nanfang Hospital, Southern Medical University - Guangzhou
  • The Chinese University of Hong Kong - Hong Kong
  • Post Graduate Institute of Medical Education and Research - Chandigarh
  • Asian Institute of Gastroenterology - Hyderabad
  • Baldota Institute of Digestive Sciences - Mumbai
  • Deenanath Mangeshkar Hospital & Research Center - Pune

Maryland

  • Johns Hopkins Hospital - Baltimore

Trial Details

FieldValue
Enrollment Target 81 participants
Start Date 2023-12-01
Est. Completion 2026-10-31
Phase NA
Chinese University of Hong Kong

1 total trials

What NCT06042127 shows while recruiting

NCT06042127 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 130-participant average among 7 other Achalasia trials with a reported enrollment target (38% lower).

The record links to 1 condition, with Achalasia appearing as the primary indexed condition, and to 2 interventions - of which POEM-F is the first listed.

NCT06042127 lists 7 locations in 2 states (Other, Maryland).

Frequently Asked Questions

What is clinical trial NCT06042127 about?

NCT06042127 is a clinical study titled "POEM-F for Achalasia International Study". Per-oral endoscopic myotomy (POEM) has emerged as the endoscopic treatment of choice for achalasia, offering comparable symptom relief with laparoscopic Heller's cardiomyotomy. The main concern with POEM is the higher incidence of post-procedure gastroesophageal reflux disease (GERD), occurring in u...

What is the current status of trial NCT06042127?

This trial is currently recruiting. It is a NA study. The enrollment target is 81 participants. The study started on 2023-12-01. Estimated completion is 2026-10-31.

What conditions does trial NCT06042127 study?

This clinical trial studies the following conditions: Achalasia.

What interventions are being tested in trial NCT06042127?

The interventions under investigation include: POEM-F (PROCEDURE), Conventional POEM (PROCEDURE).

Who is sponsoring clinical trial NCT06042127?

This trial is sponsored by Chinese University of Hong Kong, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06042127 being conducted?

This trial has 7 study locations across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Achalasia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04966481 · 81 participants · Phase 3

    Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor

  • NCT05109429 · 81 participants · NA

    Developing a Clinical Outcome Assessment for Opioid Craving

  • NCT05112601 · 81 participants · Phase 2

    Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

  • NCT05305911 · 81 participants · Phase 2

    Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06042127, the US trial registry maintained by the National Library of Medicine. NCT06042127 (small enrollment · multi site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.